Theranyx is a French biotech company founded in 2010 on a unique technology platform designed for the development of novel therapeutic solutions for the treatment of cancer.
Our platform enables us to overexpress and purify membrane receptors in stable and functional conformations that retain their drug-binding characteristics.
For the first time, contemporary drug discovery approaches, such as crystallisation and structure-based design, alongside biophysical analysis of ligand interactions, can now be applied to membrane proteins.
In combination with its receptor expression/purification platform, Theranyx is developing a wide range of compact binder libraries of various properties, including camel antibody fragments (VHH/Nanobodies) from immunised animals capable of competing against human antibodies for strategic binding sites involved in the modulation of membrane protein function.
This unique approach is expected to radically improve the chances of finding both functional molecules and new tools for membrane protein crystallisation and structure resolution which will enable the development of safe and very selective drug candidates.
Our unique expertise is accessible as a fee-for-service agreement for research teams involved in challenging projects requiring membrane receptor purification and X-ray structure resolution, as well as functional binder development on both membrane receptors and soluble proteins.